Bisnis.com, JAKARTA – Pharmaceutical companies are capital intensive industries and require trained human resources (HR). For that to unite the scattered companies into a tactical step to win the market.
On this basis, PT Kalbe Farma Tbk. (KLBF) decided to merge its subsidiary into the parent entity. The merged companies were PT Dankos Laboratories Tbk (DNKS) and PT Enseval into PT Kalbe Farma Tbk.
Bisnis Indonesia, 17 November 2005 edition reports that this corporate action will be approved by investors under the title ‘The Merger of Kalbe, Dankos & Enseval is suspected to be smooth.’
The report stated that the merger will run smoothly after all creditors, including foreigners, have given their approval. Pharmaceutical and health food companies have held a meeting to request merger licenses with creditors in floating rate notes (FRN) of US $ 28 million in Hong Kong. Kalbe itself has total debts of up to US $ 78 million.
According to Vidjongtius, at that time as Director of Kalbe, all creditors had approved the merger plan, without asking for any conditions.
– .
